412 related articles for article (PubMed ID: 31608537)
1. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T
Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537
[TBL] [Abstract][Full Text] [Related]
2. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
3. A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114).
Sakashita H; Uchibori K; Jin Y; Tsutsui T; Honda T; Sakakibara R; Mitsumura T; Nukui Y; Shirai T; Masuo M; Suhara K; Furusawa H; Yamashita T; Ohba T; Saito K; Takagiwa J; Miyashita Y; Inase N; Miyazaki Y
Thorac Cancer; 2022 May; 13(9):1267-1275. PubMed ID: 35322551
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
5. Real-World Evidence of Safety and Efficacy of Carboplatin plus Nanoparticle Albumin-Bound Paclitaxel in Patients with Advanced Non-Small-Cell Lung Cancer and Preexisting Interstitial Lung Disease: A Retrospective Study.
Araya T; Kita T; Ueda T; Terada N; Sakai T; Yamamura K; Kurokawa K; Uchida Y; Sone T; Kimura H; Kasahara K
Can Respir J; 2019; 2019():5315903. PubMed ID: 31015884
[TBL] [Abstract][Full Text] [Related]
6. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.
Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J
J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
[TBL] [Abstract][Full Text] [Related]
9. Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Nakao A; Uchino J; Igata F; On R; Ikeda T; Yatsugi H; Hirano R; Sasaki T; Tanimura K; Imabayashi T; Tamiya N; Kaneko Y; Yamada T; Nagata N; Watanabe K; Kishimoto J; Takayama K; Fujita M
Invest New Drugs; 2018 Oct; 36(5):903-910. PubMed ID: 29846848
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer.
Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M
BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
15. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
[TBL] [Abstract][Full Text] [Related]
17. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE
Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]